Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Kidney Cancer.
The Kidney Cancer Therapeutics and Diagnostics Market size is estimated at USD 6.92 billion in 2024, and is expected to reach USD 8.78 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.86% during the forecast period (2024-2029).
According to the World Cancer Research Fund International, kidney cancer is the 10th most common cancer in men and the 13th most common cancer in women.
The market is primarily driven by the increase in the prevalence of kidney cancer and increased research and development expenditures from pharmaceutical companies. According to a report by the International Kidney Cancer Coalition in July 2021, each year, around 431,000 people worldwide are diagnosed with kidney cancer. Thus, with the growing prevalence of kidney cancer, it is expected that the demand for kidney cancer therapeutics and diagnostics is likely to increase over the forecast period.
The ten countries with the highest rates of kidney cancer and the highest number of deaths from kidney cancer in 2022 (ranked in order) were China, The United States, Russia, Japan, Germany, India, France, UK, Italy, and Brazil. North America is anticipated to hold a significant share of the kidney cancer therapeutics and diagnostics market over the forecast period owing to major factors such as the increasing number of kidney cancer cases and product launches by the key market players.
For additional information on Kidney Cancer, please review the video by Medical Centric.